TORONTO--(BUSINESS WIRE)--Data presented at the 44th Annual Meeting of the Infectious Diseases Society of America (IDSA) examined the outcome of short-course treatment with FACTIVE(R) (gemifloxacin mesylate) tablets, Oscient Pharmaceuticals Corporation’s (Nasdaq: OSCI) lead antibiotic product, in patients with co-morbidities and community-acquired pneumonia (CAP). IDSA is an international meeting for infectious diseases experts to discuss the latest scientific and clinical developments in the field.
